BRD2 and colorectal carcinoma: Significant elevation in protein paucimannosylation in the CRC TUM was observed across all disease stages compared to NAT and in PBMCs from CRC patients with advanced disease (stage III–IV) relative to PBMCs from normal controls (Fig. 1D).